iMD Companies, Inc. (ICBU)
USD 0.0
(-12.5%)
USD 0.0
(-12.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -200.63 Thousand USD | 36.24% |
| 2022 | -314.69 Thousand USD | -100.15% |
| 2021 | -157.23 Thousand USD | -116.6% |
| 2020 | -72.59 Thousand USD | -82.74% |
| 2019 | -39.72 Thousand USD | 91.46% |
| 2018 | -464.92 Thousand USD | -2486.96% |
| 2017 | -17.97 Thousand USD | -106.14% |
| 2016 | 292.56 Thousand USD | 135.09% |
| 2015 | -833.71 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -60.97 Thousand USD | 4.81% |
| 2024 Q1 | -64.05 Thousand USD | -10.07% |
| 2023 FY | -200.63 Thousand USD | 36.24% |
| 2023 Q3 | -34.76 Thousand USD | -11.09% |
| 2023 Q1 | -76.38 Thousand USD | -45.39% |
| 2023 Q2 | -31.29 Thousand USD | 59.03% |
| 2023 Q4 | -58.19 Thousand USD | -67.42% |
| 2022 Q2 | -101.61 Thousand USD | 22.03% |
| 2022 FY | -314.69 Thousand USD | -100.15% |
| 2022 Q3 | -30.22 Thousand USD | 70.25% |
| 2022 Q4 | -52.53 Thousand USD | -73.82% |
| 2022 Q1 | -130.31 Thousand USD | -513.41% |
| 2021 Q2 | -38.6 Thousand USD | -24.59% |
| 2021 Q4 | -21.24 Thousand USD | 68.01% |
| 2021 Q3 | -66.4 Thousand USD | -72.04% |
| 2021 FY | -157.23 Thousand USD | -116.6% |
| 2021 Q1 | -30.98 Thousand USD | 0.0% |
| 2020 FY | -72.59 Thousand USD | -82.74% |
| 2019 FY | -39.72 Thousand USD | 91.46% |
| 2018 FY | -464.92 Thousand USD | -2486.96% |
| 2017 FY | -17.97 Thousand USD | -106.14% |
| 2016 FY | 292.56 Thousand USD | 135.09% |
| 2015 FY | -833.71 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 85.77% |
| Arrayit Corporation | -3.31 Million USD | 93.949% |
| Atlantic International Corp. | -5.62 Million USD | 96.435% |
| Biocept, Inc. | -32.08 Million USD | 99.375% |
| Bioqual, Inc. | 483.48 Thousand USD | 141.498% |
| CardioGenics Holdings Inc | -1.91 Million USD | 89.53% |
| DermTech, Inc. | -100.88 Million USD | 99.801% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.01% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 99.071% |
| IDenta Corp. | 14.64 Thousand USD | 1470.09% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 125.017% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 618.587% |
| InVitro International | 1553.00 USD | 13019.253% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 97.665% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -245.257% |
| Medical Imaging Corp. | -3.02 Million USD | 93.363% |
| NovelStem International Corp. | -4.18 Million USD | 95.208% |
| Optigenex Inc. | -2.89 Million USD | 93.076% |
| PharmChem, Inc. | 845.1 Thousand USD | 123.741% |
| Proteome Sciences plc | -2.44 Million USD | 91.787% |
| Response Genetics, Inc | -20.18 Million USD | 99.006% |
| Rennova Health, Inc. | -3.29 Million USD | 93.907% |
| RushNet, Inc. | -607.02 Thousand USD | 66.948% |
| ScreenPro Security Inc. | -2.24 Million USD | 91.078% |
| Stella Diagnostics Inc. | -5.7 Million USD | 96.485% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 98.242% |
| Todos Medical Ltd. | -24.99 Million USD | 99.197% |